BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction
NCT:NCT02880618 · RECRUITING
广告
NCT编号NCT02880618
状态RECRUITING
开始日期2016-12-13
SponsorCVRx, Inc. (INDUSTRY)
First posted
Last updated
简要摘要
The purpose of this registry (NCT02880618) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the CE-Marked indication for heart failure with reduced ejection fraction (HFrEF).
官方来源
在 ClinicalTrials.gov 上查看 →数据来自 ClinicalTrials.gov API。有关最新状态,请参阅官方记录。